z-logo
open-access-imgOpen Access
Novel Agents for the Management of Endocrine Resistant Breast Cancer
Author(s) -
Sonya Reid,
Ingrid A. Mayer
Publication year - 2018
Publication title -
current breast cancer reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.467
H-Index - 18
eISSN - 1943-4596
pISSN - 1943-4588
DOI - 10.1007/s12609-018-0298-3
Subject(s) - surgical oncology , medicine , breast cancer , endocrine system , oncology , general surgery , cancer , hormone
Most women with hormone receptor (HR)-positive, HER2-negative (HR+/HER2-) breast cancer will ultimately develop endocrine-resistant disease, either primary or acquired. This review will discuss the proposed mechanisms underlying endocrine resistance and key advances in the treatment of endocrine-resistant breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here